A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care

Swedish Orphan Biovitrum2 sites in 2 countries1,658 target enrollmentMarch 2014

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Haemophilia A
Sponsor: Swedish Orphan Biovitrum
Enrollment: 1658
Locations: 2
Primary Endpoint: Total dose (IU) issued of Factor IX during a 12 month period
Status: Completed
Last Updated: 10 years ago

To describe the current treatment practice during 12 months for previously treated patients diagnosed with haemophilia A or haemophilia B.

The study population consists of patients with a diagnosis of ICD10: haemophilia A D66.9 or haemophilia B D67.9.

Registry

clinicaltrials.gov

Start Date

March 2014

End Date

September 2015

Last Updated

10 years ago

Study Type

Observational

Sex

Male

Sponsor

Responsible Party

Sponsor

•Male patients with severe or moderate haemophilia A or haemophilia B.
•Treatment with Factor VIII/Factor IX products initiated at least 24 months before inclusion in the study.
•Informed consent is obtained from the patient or patient's legal representative (as applicable according to legal regulation).